Andrew Brunner, MD, Massachusetts General Hospital, Boston, MA, discusses avenues for classifying and treating patients with low-risk myelodysplastic syndromes (LR-MDS). Dr Brunner highlights the erythroid maturation agent luspatercept, which was demonstrated to be effective in a press release on the Phase III COMMANDS study (NCT03682536). Dr Brunner further notes the importance of properly classifying patients with truly low-risk disease and improving the sequencing of therapies for this group. This interview took place at the 17th International Congress on Myelodysplastic Syndromes (MDS) 2023, held in Marseille, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть